News & Updates

Treatment with inclisiran in real-world settings appears to produce significant reductions in low-density lipoprotein cholesterol (LDL-C) at 2 months with good tolerability, with results consistent with that reported in previous trials, according to a study.

New drug applications approved by US FDA as of 01 - 15 December 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Lenadogene nolparvovec is well tolerated among patients with Leber hereditary optic neuropathy, being associated with mostly mild ocular side effects that can be resolved with conventional ophthalmologic treatments, according to the results of the LHON study.

The three-drug regimen consisting of topotecan, paclitaxel, and bevacizumab prolongs progression-free survival in women with recurrent high-grade neuroendocrine carcinoma of the cervix, as shown in a study.

IV sotalol administered rapidly as a loading dose to initiate oral sotalol therapy is feasible and safe for rhythm control in individuals with atrial fibrillation (AF), the DASH-AF study finds.